4.7 Article

Apigenin Protects Endothelial Cells from Lipopolysaccharide (LPS)-Induced Inflammation by Decreasing Caspase-3 Activation and Modulating Mitochondrial Function

Journal

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 14, Issue 9, Pages 17664-17679

Publisher

MDPI
DOI: 10.3390/ijms140917664

Keywords

inflammation; flavonoids; metabolism; mitochondrial dysfunction

Funding

  1. Public Health Preparedness for infectious diseases (PHPID)-Program pre-doctoral fellowship
  2. [RO1HL075040-01]

Ask authors/readers for more resources

Acute and chronic inflammation is characterized by increased reactive oxygen species (ROS) production, dysregulation of mitochondrial metabolism and abnormal immune function contributing to cardiovascular diseases and sepsis. Clinical and epidemiological studies suggest potential beneficial effects of dietary interventions in inflammatory diseases but understanding of how nutrients work remains insufficient. In the present study, we evaluated the effects of apigenin, an anti-inflammatory flavonoid abundantly found in our diet, in endothelial cells during inflammation. Here, we show that apigenin reduced lipopolysaccharide (LPS)-induced apoptosis by decreasing ROS production and the activity of caspase-3 in endothelial cells. Apigenin conferred protection against LPS-induced mitochondrial dysfunction and reestablished normal mitochondrial complex I activity, a major site of electron leakage and superoxide production, suggesting its ability to modulate endothelial cell metabolic function during inflammation. Collectively, these findings indicate that the dietary compound apigenin stabilizes mitochondrial function during inflammation preventing endothelial cell damage and thus provide new translational opportunities for the use of dietary components in the prevention and treatment of inflammatory diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

A Molecular Mechanism Underlying Genotype-Specific Intrahepatic Cholestasis Resulting From MYO5B Mutations

Arend W. Overeem, Qinghong Li, Yi-Ling Qiu, Fernando Carton-Garcia, Changsen Leng, Karin Klappe, Just Dronkers, Nai-Hua Hsiao, Jian-She Wang, Diego Arango, Sven C. D. van Ijzendoorn

HEPATOLOGY (2020)

Article Nanoscience & Nanotechnology

Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells

Petra Gener, Sara Montero, Helena Xandri-Monje, Zamira V. Diaz-Riascos, Diana Rafael, Fernanda Andrade, Francesc Martinez-Trucharte, Patricia Gonzalez, Joaquin Seras-Franzoso, Albert Manzano, Diego Arango, Joan Sayos, Ibane Abasolo, Simo Schwartz

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)

Review Oncology

PVT1 Long Non-coding RNA in Gastrointestinal Cancer

Agueda Martinez-Barriocanal, Diego Arango, Higinio Dopeso

FRONTIERS IN ONCOLOGY (2020)

Article Pharmacology & Pharmacy

Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells

Sara Montero, Joaquin Seras-Franzoso, Fernanda Andrade, Francesc Martinez-Trucharte, Mireia Vilar-Hernandez, Manuel Quesada, Helena Xandri, Diego Arango, Ibane Abasolo, Diana Rafael, Simo Schwartz

PHARMACEUTICS (2020)

Article Chemistry, Multidisciplinary

Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo

Fernanda Andrade, Diana Rafael, Mireia Vilar-Hernandez, Sara Montero, Francesc Martinez-Trucharte, Joaquin Seras-Franzoso, Zamira Diaz-Riascos, Ana Boullosa, Natalia Garcia-Aranda, Patricia Camara-Sanchez, Diego Arango, Marika Nestor, Ibane Abasolo, Bruno Sarmento, Simo Schwartz

Summary: The use of CD44v6-targeted polymeric micelles loaded with niclosamide shows promise as a therapeutic strategy against colorectal cancer stem cells and circulating tumor cells, with potential to improve clinical outcomes.

JOURNAL OF CONTROLLED RELEASE (2021)

Article Cell Biology

Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis

Oliver H. Voss, Daniel Arango, Justin C. Tossey, Miguel A. Villalona Calero, Andrea Doseff

Summary: Apigenin sensitizes primary lung cancer cells to TRAIL-induced apoptosis through reprogramming alternative splicing of key TRAIL/DISC components and directly binding heat shock protein 70 to promote cell death. These findings emphasize the synergies between diet and cancer treatments, providing new avenues for improved cancer therapies.

CELL DEATH & DISEASE (2021)

Article Oncology

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

Sarah Bazzocco, Higinio Dopeso, Agueda Martinez-Barriocanal, Estefania Anguita, Rocio Nieto, Jing Li, Elia Garcia-Vidal, Valentina Maggio, Paulo Rodrigues, Priscila Guimaraes de Marcondes, Simo Schwartz, Lauri A. Aaltonen, Alex Sanchez, John M. Mariadason, Diego Arango

Summary: In this study, a set of 382 genes potentially silenced by promoter methylation in colorectal cancer were identified, which could significantly contribute to the oncogenic process. The epigenetically silenced gene ZBTB18 was found to have tumor suppressor activity and serve as a novel prognostic marker for patients with locally advanced colorectal cancer.

CLINICAL EPIGENETICS (2021)

Article Pharmacology & Pharmacy

Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation

Thibaut Fourniols, Valentina Maggio, Diana Rafael, Ariana Colaco, Elia Garcia Vidal, Alessandra Lopes, Simo Schwartz, Agueda Martinez-Barriocanal, Veronique Preat, Diego Arango

Summary: In this study, we evaluated the therapeutic effect of two new nano-formulations of BETi JQ1 for the treatment of colorectal cancer. The results showed that although nanoencapsulation improved the delivery of JQ1 to tumors, it did not enhance its anticancer effect. Additionally, MYC inhibition did not affect the efficacy of JQ1 in the CT26 CRC mouse model.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2022)

Article Biochemistry & Molecular Biology

Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo

Irina Giralt, Gabriel Gallo-Oller, Natalia Navarro, Patricia Zarzosa, Guillem Pons, Ainara Magdaleno, Miguel F. Segura, Constantino Sabado, Raquel Hladun, Diego Arango, Jose Sanchez de Toledo, Lucas Moreno, Soledad Gallego, Josep Roma

Summary: The study demonstrates the therapeutic potential of DKK-1 pharmaceutical inhibition in rhabdomyosarcoma, resulting in beta-catenin activation and modulation of focal adhesion kinase, with positive effects on myogenic marker expression and a reduction in proliferation and invasion. In addition, the chemical inhibitor WAY-262611 was able to impair tumor cell survival in vivo, suggesting DKK-1 as a potential molecular target for novel therapeutic strategies in RMS patients, especially those with high DKK-1 expression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biochemistry & Molecular Biology

Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression

Ian Y. Luk, Laura J. Jenkins, Kael L. Schoffer, Irvin Ng, Janson W. T. Tse, Dmitri Mouradov, Stanislaw Kaczmarczyk, Rebecca Nightingale, Allan D. Burrows, Robin L. Anderson, Diego Arango, Higinio Dopeso, Larry Croft, Mark F. Richardson, Oliver M. Sieber, Yang Liao, Jennifer K. Mooi, Natalia Vukelic, Camilla M. Reehorst, Shoukat Afshar-Sterle, Vicki L. J. Whitehall, Lochlan Fennell, Helen E. Abud, Niall C. Tebbutt, Wayne A. Phillips, David S. Williams, Wei Shi, Lisa A. Mielke, Matthias Ernst, Amardeep S. Dhillon, Nicholas J. Clemons, John M. Mariadason

Summary: In this study, co-ordinate epigenetic inactivation of two epithelial-specific transcription factors, EHF and CDX1, was identified as a mechanism driving differentiation loss in CRCs. Re-expression of EHF and CDX1 induced extensive chromatin remodelling, transcriptional re-programming, and differentiation in poorly-differentiated CRC cells, leading to reduced growth and metastasis. These findings reveal a novel mechanism driving epithelial de-differentiation and tumor progression in CRC.

CELL DEATH AND DIFFERENTIATION (2022)

Article Biochemistry & Molecular Biology

Direct epitranscriptomic regulation of mammalian translation initiation through N4-acetylcytidine

Daniel Arango, David Sturgill, Renbin Yang, Tapan Kanai, Paulina Bauer, Jyoti Roy, Ziqiu Wang, Masaki Hosogane, Sarah Schiffers, Shalini Oberdoerffer

Summary: mRNA function is affected by modifications that can alter the behavior of nucleobases. A specific modification can have different impacts on mRNA translation depending on its position. The acetylation of cytidine (ac4C) within protein-coding sequences enhances translation, while ac4C within 5' UTRs affects protein synthesis at the initiation level. The acetylation promotes initiation at upstream sequences and competitively inhibits annotated start codons. Additionally, ac4C within AUG-flanking Kozak sequences directly impedes initiation at optimal AUG contexts.

MOLECULAR CELL (2022)

Article Biochemistry & Molecular Biology

Myosin Vb as a tumor suppressor gene in intestinal cancer

Fernando Carton-Garcia, Bruno Brotons, Estefania Anguita, Higinio Dopeso, Jordi Tarragona, Rocio Nieto, Elia Garcia-Vidal, Irati Macaya, Zsuzsanna Zagyva, Mariona Dalmau, Manuel Sanchez-Martin, Sven C. D. van Ijzendoorn, Stefania Landolfi, Javier Hernandez-Losa, Simo Schwartz Jr, Xavier Matias-Guiu, Santiago Ramon y Cajal, Agueda Martinez-Barriocanal, Diego Arango

Summary: Loss of myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Reduced expression of myosin Vb in tumors identifies a subset of poor prognosis colorectal cancer patients.

ONCOGENE (2022)

Article Oncology

Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs

Patricia Gonzalez-Callejo, Petra Gener, Zamira Diaz-Riascos, Sefora Conti, Patricia Camara-Sanchez, Roger Riera, Sandra Mancilla, Miguel Garcia-Gabilondo, Vicente Peg, Diego Arango, Anna Rosell, Anna Labernadie, Xavier Trepat, Lorenzo Albertazzi, Jr Simo Schwartz, Joaquin Seras-Franzoso, Ibane Abasolo

Summary: Tumor-secreted extracellular vesicles play a crucial role in the establishment and growth of metastatic tumors. The diversity among these vesicles, particularly in triple-negative breast cancer, has not been fully explored. This study found that vesicles secreted by cancer stem cells and differentiated cancer cells have distinct effects on the tumor microenvironment, promoting different aspects of tumor growth and metastasis.

INTERNATIONAL JOURNAL OF CANCER (2023)

Review Pharmacology & Pharmacy

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Diana Rafael, Marcelo Guerrero, Adolfo Marican, Diego Arango, Bruno Sarmento, Roser Ferrer, Esteban F. Duran-Lara, Simon J. Clark, Simo Schwartz

Summary: Slow-release delivery systems are crucial for long-term sustained treatments of retinal diseases. Hydrogels, especially temperature-responsive hydrogels, have been studied as promising delivery vehicles for intravitreal injection of retinal therapies.

PHARMACEUTICS (2023)

Article Cell Biology

Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer

Meenakshi Sudhakaran, Tatiana Garcia Navarrete, Katherine Mejia-Guerra, Eric Mukundi, Timothy D. Eubank, Erich Grotewold, Daniel Arango, Andrea I. Doseff

Summary: Apigenin has been found to reprogram the transcriptome of triple-negative breast cancer (TNBC), inducing apoptosis and inhibiting tumor growth, offering new options for TNBC treatments.

CELL DEATH & DISEASE (2023)

No Data Available